Artelo Biosciences, Inc. 宣布,其候选药物 Art26.12 在一项非临床骨关节炎研究中,展现出了与常用镇痛抗炎药萘普生(Naproxen)相当的疗效。这一积极发现为该公司针对疼痛管理的新药研发管线注入了新的动力。
Artelo Biosciences, Inc. 宣布,其候选药物 Art26.12 在一项非临床骨关节炎研究中,展现出了与常用镇痛抗炎药萘普生(Naproxen)相当的疗效。这一积极发现为该公司针对疼痛管理的新药研发管线注入了新的动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.